OncoSec Medical Incorporated

Sümbol: ONCS

NASDAQ

0.2772

USD

Turuhind täna

-0.0457
P/E suhe
-0.0010
PEG suhe
1.65M
MRK Cap
0.00%
DIV tootlus

OncoSec Medical Incorporated (ONCS) Finantsaruanded

Q: Mis on OncoSec Medical Incorporated (ONCS) koguvara?

OncoSec Medical Incorporated (ONCS) koguvara on .

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete OncoSec Medical Incorporated (ONCS) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes OncoSec Medical Incorporated fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009
balance-sheet.row.cash-and-short-term-investments	41.19	12.3	46	20.4	25.1	27	11.4	28.7	32	37.9	5	5.1	2.5	0	0	0
balance-sheet.row.short-term-investments	0	0	0	0	0	23.2	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.inventory	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	10.25	2.9	3.2	2.5	3.4	1.6	1.1	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-current-assets	51.44	15.2	49.2	22.8	28.5	28.6	12.5	29.4	33.6	38.3	5.2	5.5	2.9	0	0	0
balance-sheet.row.property-plant-equipment-net	17.97	5.6	6.4	6.8	1	1.3	2.4	2.8	1.8	0.6	0.2	0.1	0.1	0	0	0
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	1.48	0.4	0.4	0	0	0	0	0	0	0.5	1.2	1.9	2.7	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	1.48	0.4	0.4	0	0	0	0	0	0	0.5	1.2	1.9	2.7	0	0	0
balance-sheet.row.long-term-investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	2.29	0.6	0.3	0.3	0.4	0.4	0.3	0.2	0.2	0	0	0	0	0	0	0
balance-sheet.row.total-non-current-assets	21.74	6.6	7.1	7.1	1.4	1.6	2.7	3	2	1.1	1.3	1.9	2.8	0	0	0
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	73.18	21.9	56.3	29.9	29.9	30.2	15.2	32.4	35.6	39.4	6.5	7.4	5.7	0	0	0
balance-sheet.row.account-payables	0	0	0	0	0	0	3.3	0	0	1.2	0.7	0.4	0.4	0	0	0
balance-sheet.row.short-term-debt	6.22	2	2.1	1.5	0.1	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	14.19	4.1	5.2	6.4	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	19.24	4.6	5.9	8.2	4.9	5.8	0.1	3.5	2.9	0.1	1	1.6	6.2	0	0	0
balance-sheet.row.total-non-current-liabilities	34.19	9.1	10.2	6.4	0.6	1.5	1.1	0.9	0	1.2	0.7	1	1.5	0	0	0
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	-1.2	-0.7	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	16.39	5.2	6.1	6.4	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	59.65	15.8	18.2	16	5.6	7.3	4.5	4.4	2.9	1.3	1.8	3	8	0	0	0
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0.01	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-1158.6	-286	-251.8	-206.6	-164.4	-134.1	-94.9	-73.5	-46.6	-25.4	-13.4	-6.2	-3.8	-0.1	0	0
balance-sheet.row.accumulated-other-comprehensive-income-loss	1.48	0.2	-0.1	0	0.2	0	0	-0.4	-0.3	-0.1	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1170.65	291.8	289.9	220.5	188.5	157	105.6	101522492	79276.8	63406.6	18.1	10.6	1.5	0	0	0
balance-sheet.row.total-stockholders-equity	13.54	6.1	38.1	13.9	24.3	22.9	10.7	28.1	32.7	38.1	4.7	4.4	-2.4	0	0	0
balance-sheet.row.total-liabilities-and-stockholders-equity	73.18	21.9	56.3	29.9	29.9	30.2	15.2	32.4	35.6	39.4	6.5	7.4	5.7	0	0	0
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	13.54	6.1	38.1	13.9	24.3	22.9	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	73.18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	0	0	0	0	0	23.2	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-debt	20.41	6.2	7.3	7.8	0.1	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-debt	-20.78	-6.1	-38.6	-12.5	-25.1	-3.8	-11.4	-28.7	-32	-37.9	-5	-5.1	-2.5	0	0	0

Rahavoogude aruanne

OncoSec Medical Incorporated finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009
cash-flows.row.net-income	-29.39	-34.2	-45.2	-42.3	-30.3	-39.1	-21.4	-26.9	-21.2	-12	-7.2	-2.4	-3.8
cash-flows.row.depreciation-and-amortization	0.94	1.1	1.1	1	0.2	0.3	0.4	0.4	0.7	0.8	0.7	0.7	0.3
cash-flows.row.deferred-income-tax	0	0	-0.8	-0.1	0.2	0	0	0	0	0	0	0	-67.8
cash-flows.row.stock-based-compensation	1.28	1.6	5.1	3.5	3.5	8.3	4	6.1	2.6	1.8	0.5	0.3	67.8
cash-flows.row.change-in-working-capital	2.05	-1.2	-2.5	3.8	-3.5	2.2	-0.3	2.3	0.3	0.3	0.3	0	0.2
cash-flows.row.account-receivables	0	0	0	0	0	0	0	0	0	0	0	0	-391.2
cash-flows.row.inventory	0	0	0	0	0	0	0	0	0	0	0	0	38
cash-flows.row.account-payables	-1.38	-1.4	-2.6	3.6	-0.7	0	-0.2	0.9	1.1	0.7	0.3	0	353.2
cash-flows.row.other-working-capital	3.43	0.2	0.1	0.2	-2.8	2.2	-0.1	1.5	-0.8	-0.4	0	0	0.2
cash-flows.row.other-non-cash-items	0.12	0.6	0.5	0.9	0.8	5.2	0	0.3	0.1	0.2	0.1	-2.9	2
cash-flows.row.net-cash-provided-by-operating-activities	-24.99	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.24	-0.2	-0.8	0	0	-0.1	0	-1.6	-1.4	-0.5	-0.1	-0.1	-0.3
cash-flows.row.acquisitions-net	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	0	0	0	0	0	-25.5	0	0	0	0	0	0	0
cash-flows.row.sales-maturities-of-investments	0	0	0	0	23.2	2.3	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	-0.26	-0.2	-0.8	0	23.2	-23.3	0	-1.6	-1.4	-0.5	-0.1	-0.1	-0.3
cash-flows.row.debt-repayment	-1.15	-1.3	-0.6	-0.1	-0.1	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-issued	0.04	0	62.8	30	27.9	32.3	0	17.5	13.6	27.9	7.2	7.8	4.1
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	4.65	0.1	6	-1.5	-0.6	6.6	0.1	-1.4	-0.3	14.4	-1.7	-0.8	0
cash-flows.row.net-cash-used-provided-by-financing-activities	3.54	-1.2	68.2	28.4	27.2	38.9	0.1	16.1	13.3	42.4	5.5	7	4.1
cash-flows.row.effect-of-forex-changes-on-cash	-0.08	-0.1	0	0	-0.1	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-21.55	-33.7	25.6	-4.8	21.3	-7.6	-17.3	-3.3	-5.8	32.9	-0.2	2.7	2.5
cash-flows.row.cash-at-end-of-period	41.19	12.3	46	20.4	25.1	3.8	11.4	28.7	32	37.9	5	5.1	2.5
cash-flows.row.cash-at-beginning-of-period	62.74	46	20.4	25.1	3.8	11.4	28.7	32	37.9	5	5.1	2.5	0
cash-flows.row.operating-cash-flow	-24.99	-32.1	-41.8	-33.1	-29	-23.2	-17.3	-17.8	-17.7	-9	-5.5	-4.2	-1.3
cash-flows.row.capital-expenditure	-0.24	-0.2	-0.8	0	0	-0.1	0	-1.6	-1.4	-0.5	-0.1	-0.1	-0.3
cash-flows.row.free-cash-flow	-25.24	-32.4	-42.6	-33.1	-29	-23.3	-17.4	-19.4	-19.1	-9.5	-5.6	-4.3	-1.6

Kasumiaruande rida

OncoSec Medical Incorporated tulud muutusid võrreldes eelmise perioodiga NaN%. ONCS brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009
income-statement-row.row.total-revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.cost-of-revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.gross-profit	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	21.77	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	10.88	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0.06	0	0	0.2	0.4	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.operating-expenses	32.65	37	48.4	43.4	30.4	36.1	21.4	26.9	21.2	11.9	7.1	5.5	1.7	0	0	0
income-statement-row.row.cost-and-expenses	32.65	37	48.4	43.4	30.4	36.1	21.4	26.9	21.2	11.9	7.1	5.5	1.7	0	0	0
income-statement-row.row.interest-income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	0.05	0	0	0	0	6.4	0	0	0	0	0.1	-3.2	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-0.07	-0.5	0.8	0.3	0.1	-3	0	0	0	0	-0.1	3.2	-2.1	0	0	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0.06	0	0	0.2	0.4	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.total-operating-expenses	-0.07	-0.5	0.8	0.3	0.1	-3	0	0	0	0	-0.1	3.2	-2.1	0	0	0
income-statement-row.row.interest-expense	0.05	0	0	0	0	6.4	0	0	0	0	0.1	-3.2	0	0	0	0
income-statement-row.row.depreciation-and-amortization	0.99	1.1	1.1	1.2	0.7	3.7	0.4	0.4	0.7	0.8	0.7	0.7	0.3	0	0	0
income-statement-row.row.ebitda-caps	-31.66	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-32.65	-37	-48.4	-43.4	-30.4	-36.1	-21.4	-26.9	-21.2	-11.9	-7.1	-5.5	-1.7	0	0	0
income-statement-row.row.income-before-tax	-32.72	-37.5	-47.6	-43.1	-30.3	-39.1	-21.4	-26.9	-21.2	-12	-7.1	-2.4	-3.8	0	0	0
income-statement-row.row.income-tax-expense	-2.58	-3.3	-2.4	-0.9	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.net-income	-30.14	-34.2	-45.2	-42.3	-30.3	-39.1	-21.4	-26.9	-21.2	-12	-7.2	-2.4	-3.8	0	0	0